Q1 Financial Results 2025-26

Beximco Pharmaceuticals PLC

24 June 2026

 

24 June 2026

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

BEXIMCO PHARMACEUTICALS PLC.

Q1 Financial Results 2025-26

Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its unaudited results for the three-month period ended 30 September 2025.

Financial Highlights (Consolidated)

First quarter ended 30 September 2025

·      Net revenue increased 17.8% to Bangladesh Taka ("BDT") 13,794.8m / £85.0m (2023-24: BDT 11,714.0m / £74.0m

o  Domestic sales increased 17.8% to BDT 13,717.4m / £84.5m (2023-24: BDT 11,640.6m / £73.6m)

o  Export sales increased 5.4% to BDT 77.4m / £0.5m (2023-24: BDT 73.4m / £0.5m)

·      Profit after tax increased 41.9% to BDT 2,401.3m / £14.8m (2023-24: BDT 1,691.9m / £10.7m)

The detailed accounts can be viewed at the Company website: www.beximcopharma.com

For a summary of financial and operational highlights for the period from 1 January 2025 to 31 March 2026, please refer to the previous announcement titled: "Financial Results for the Periods from 1 January 2025 to 31 March 2026", released today.

Exchange rates of £1=Taka 162.3035 for 30 September 2025 and £1=Taka 158.2481 for 30 September 2024 have been used in this announcement.

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

S M Rabbur Reza, Chief Operating Officer

Tel: [phone], Ext. 20111

Mohammad Ali Nawaz, Chief Financial Officer

Tel: [phone], Ext. 20030

Mohammad Asad Ullah, FCS

Executive Director & Company Secretary

Tel: [phone], Ext. 10140

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: [phone] / 3555 

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: [phone]

FTI Consulting

Simon Conway / Sam Purewal / Lucy Molloy

Tel: [phone]

Notes to Editors

About Beximco Pharmaceuticals PLC.

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated statement of financial position (Un-audited)

As at September 30, 2025

	September 30, 2025		Taka '000 June 30, 2025
ASSETS
Non-current assets	49,883,483		49,461,242
Property, plant and equipment	43,981,153		43,541,872
Right-of-use assets	463,968		485,613
Intangible assets	4,707,354		4,694,134
Deferred tax asset	35,464		44,079
Goodwill	674,570		674,570
Other investments	20,974		20,974
Current assets	25,986,643		23,786,005
Inventories	14,234,467		13,586,476
Spares and supplies	804,369		799,644
Trade and other receivables	3,724,128		3,628,788
Loans, advances, deposits and prepayments	3,191,326		2,814,492
Advance income tax	383,233		356,508
Short term investment	1,000,000		900,000
Cash and cash equivalents	2,649,120		1,700,097
TOTAL ASSETS	75,870,126		73,247,247
SHAREHOLDERS' EQUITY AND LIABILITIES
Equity attributable to the owners of the company	55,470,457		53,107,137
Share capital	4,461,121		4,461,121
Share premium	5,269,475		5,269,475
Excess of issue price over face value of GDRs	1,689,637		1,689,637
Capital reserve on merger	294,951		294,951
Revaluation surplus	1,133,107		1,133,870
Unrealized gain/(loss)	18,149		18,149
Retained earnings	42,604,017		40,239,934
Non-controlling interest	4,015,661		3,977,499
TOTAL EQUITY	59,486,118		57,084,636
Non-current liabilities	8,105,401		7,769,471
Long term borrowings-net of current maturity	1,271,390		1,503,595
Liability for gratuity, pension and WPPF	4,251,222		3,690,096
Deferred tax liability	2,582,789		2,575,780
Current liabilities	8,278,607		8,393,140
Short term borrowings	2,033,371		2,025,394
Long term borrowings-current maturity	1,200,490		1,436,752
Trade and other payables	2,823,065		2,925,994
Accrued expenses	1,275,791		1,174,096
Dividend payable	138,414		302,272
Income tax payable	807,476		528,632
TOTAL LIABILITIES	16,384,008		16,162,611
TOTAL EQUITY AND LIABILITIES	75,870,126		73,247,247

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated statement of profit or loss and other comprehensive income (Un-audited)

For the period July-September 2025

			Taka '000
	July - September 2025		July - September 2024
Net revenue	13,794,829		11,713,850
Cost of goods sold	(7,132,749)		(6,305,742)
Gross profit	6,662,080		5,408,108
Operating expenses	(3,368,334)		(2,845,000)
General and administrative expenses	(354,695)		(304,448)
Selling, marketing and distribution expenses	(3,013,639)		(2,540,552)
Profit from operations	3,293,746		2,563,108
Other income	169,395		20,061
Finance cost	(186,310)		(278,444)
Profit before tax and WPPF	3,276,831		2,304,725
Contribution to WPPF	(157,156)		(110,840)
Profit before tax	3,119,675		2,193,885
Income tax expenses	(718,414)		(502,003)
Current tax	(702,569)		(500,129)
Deferred tax	(15,845)		(1,874)
Profit after tax	2,401,261		1,691,882
Profit/(loss) attributable to:
Owners of the Company	2,363,099		1,680,570
Non-controlling interest	38,162		11,312
	2,401,261		1,691,882
Other comprehensive income/(loss)	-		-
Total comprehensive income	2,401,261		1,691,882
Total comprehensive income attributable to:
Owners of the Company	2,363,099		1,680,570
Non-controlling interest	38,162		11,312
	2,401,261		1,691,882
Earnings per share (EPS)	5.30		3.77

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated statement of changes in equity (Un-audited)

For the period July-September 2025

For the period ended September 2025

Taka '000

	Share capital	Share premium	Excess of issue price over Face value of GDRs	Capital reserve on merger	Revaluation surplus	Unrealized gain/(loss)	Retained earnings	Equity attributable to owners of the company	Non-controlling interest	Total equity
Balance as on July 01, 2025	4,461,121	5,269,475	1,689,637	294,951	1,133,870	18,149	40,239,934	53,107,137	3,977,499	57,084,636
Total comprehensive income:
Profit/(loss) for the period	-	-	-	-	-	-	2,363,099	2,363,099	38,162	2,401,261
Others:
Adjustment for depreciation on revalued assets	-	-	-	-	(984)	-	984	-	-	-
Adjustment for deferred tax on revalued assets	-	-	-	-	221	-	-	221	-	221
Balance as on September 30, 2025	4,461,121	5,269,475	1,689,637	294,951	1,133,107	18,149	42,604,017	55,470,457	4,015,661	59,486,118
Net asset value (NAV) per share							Tk.	124.34

For the period ended September 2024

	Share capital	Share premium	Excess of issue price over Face value of GDRs	Capital reserve on merger	Revaluation surplus	Unrealized gain/(loss)	Retained earnings	Equity attributable to owners of the company	Non-controlling interest	Total equity
Balance as on July 01, 2024	4,461,121	5,269,475	1,689,637	294,951	1,137,306	18,148	35,079,327	47,949,965	3,952,938	51,902,903
Total comprehensive income:
Profit/(loss) for the period	-	-	-	-	-	-	1,680,570	1,680,570	11,312	1,691,882
Others:
Adjustment for depreciation on revalued assets	-	-	-	-	(1,108)	-	1,108	-	-	-
Adjustment for deferred tax on revalued assets	-	-	-	-	249	-	-	249	-	249
Balance as on September 30, 2024	4,461,121	5,269,475	1,689,637	294,951	1,136,447	18,148	36,761,005	49,630,784	3,964,250	53,595,034
Net asset value (NAV) per share							Tk.	111.25

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated statement of cash flows (Un-audited)

For the period July-September 2025

	July - September 2025		Taka '000 July - September 2024
Cash flows from operating activities
Cash receipts from customers and others	13,822,950		11,572,484
Cash paid to suppliers and employees	(10,498,856)		(9,346,118)
Cash generated from operations	3,324,094		2,226,366
Interest paid	(199,501)		(264,266)
Interest received	63,704		14,706
Income tax paid	(450,451)		(279,687)
Net cash generated from operating activities	2,737,846		1,697,119
Cash flows from investing activities
Acquisition of property, plant and equipment	(984,442)		(310,588)
Intangible assets	(92,909)		(27,560)
Disposal of property, plant and equipment	-		12,084
Short term investment	(100,000)		(250,000)
Net cash used in investing activities	(1,177,351)		(576,064)
Cash flows from financing activities
Net increase/(decrease) in long term borrowings	(463,728)		(219,109)
Net increase/(decrease) in short term borrowings	7,978		(903,361)
Dividend paid	(163,858)		(1,293)
Net cash from/(used in) financing activities	(619,608)		(1,123,763)
Increase/(decrease) in cash and cash equivalents	940,887		(2,708)
Opening cash and cash equivalents	1,700,097		854,106
Effect of exchange rate changes on cash and cash equivalents	8,136		7,967
Closing cash and cash equivalents	2,649,120		859,365
Net operating cash flows per share	6.14		3.80

 

END